VIROLOGICALLY SUPPRESSED PATIENTS
*1 patient was excluded for receiving a TDF-containing regimen instead of a TAF-containing regimen.2
†2 deaths (1 homicide and 1 unknown reason), both unrelated to treatment, occurred in the DOVATO arm.2
- Cahn P, Sierra Madero J, ArribasJR, et al. Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naïve adults with HIV-1 infection—3-year results from the GEMINI studies. Presented at: HIV Glasgow 2020; October 5-8, 2020; Virtual. Poster P018.
- van Wyk J, AjanaF, BisshopF, et al. Switching to DTG/3TC fixed-dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 96 weeks (TANGO study). Presented at: HIV Glasgow 2020; October 5-8, 2020; Virtual. Slides O441.
PM-GB-DLL-WCNT-210004 I April 2021